» Articles » PMID: 34778093

Syndecans and Their Synstatins: Targeting an Organizer of Receptor Tyrosine Kinase Signaling at the Cell-Matrix Interface

Overview
Journal Front Oncol
Specialty Oncology
Date 2021 Nov 15
PMID 34778093
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Receptor tyrosine kinases (RTKs) and integrin matrix receptors have well-established roles in tumor cell proliferation, invasion and survival, often functioning in a coordinated fashion at sites of cell-matrix adhesion. Central to this coordination are syndecans, another class of matrix receptor, that organize RTKs and integrins into functional units, relying on docking motifs in the syndecan extracellular domains to capture and localize RTKs (e.g., EGFR, IGF-1R, VEGFR2, HER2) and integrins (e.g., αvβ3, αvβ5, α4β1, α3β1, α6β4) to sites of adhesion. Peptide mimetics of the docking motifs in the syndecans, called "synstatins", prevent assembly of these receptor complexes, block their signaling activities and are highly effective against tumor cell invasion and survival and angiogenesis. This review describes our current understanding of these four syndecan-coupled mechanisms and their inhibitory synstatins (SSTN, SSTN, SSTN, SSTN and SSTN).

Citing Articles

Targeted therapy for multiple myeloma: an overview on CD138-based strategies.

Riccardi F, Tangredi C, Dal Bo M, Toffoli G Front Oncol. 2024; 14:1370854.

PMID: 38655136 PMC: 11035824. DOI: 10.3389/fonc.2024.1370854.


Thy-1 (CD90)-regulated cell adhesion and migration of mesenchymal cells: insights into adhesomes, mechanical forces, and signaling pathways.

Valdivia A, Avalos A, Leyton L Front Cell Dev Biol. 2023; 11:1221306.

PMID: 38099295 PMC: 10720913. DOI: 10.3389/fcell.2023.1221306.


Structure and function of the membrane microdomains in osteoclasts.

Hou J, Liu J, Huang Z, Wang Y, Yao H, Hu Z Bone Res. 2023; 11(1):61.

PMID: 37989999 PMC: 10663511. DOI: 10.1038/s41413-023-00294-5.


Inhibiting IGF1R-mediated Survival Signaling in Head and Neck Cancer with the Peptidomimetic SSTN.

Stueven N, Beauvais D, Hu R, Kimple R, Rapraeger A Cancer Res Commun. 2023; 3(1):97-108.

PMID: 36968227 PMC: 10035507. DOI: 10.1158/2767-9764.CRC-22-0274.


Signaling Pathways Associated with Chronic Wound Progression: A Systems Biology Approach.

Basu P, Martins-Green M Antioxidants (Basel). 2022; 11(8).

PMID: 36009225 PMC: 9404828. DOI: 10.3390/antiox11081506.

References
1.
Adams T, Epa V, Garrett T, Ward C . Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci. 2000; 57(7):1050-93. PMC: 11146944. DOI: 10.1007/PL00000744. View

2.
Ramani V, Purushothaman A, Stewart M, Thompson C, Vlodavsky I, Au J . The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J. 2013; 280(10):2294-306. PMC: 3651779. DOI: 10.1111/febs.12168. View

3.
Yang X, Dutta U, Shaw L . SHP2 mediates the localized activation of Fyn downstream of the α6β4 integrin to promote carcinoma invasion. Mol Cell Biol. 2010; 30(22):5306-17. PMC: 2976378. DOI: 10.1128/MCB.00326-10. View

4.
Rose D, Alon R, Ginsberg M . Integrin modulation and signaling in leukocyte adhesion and migration. Immunol Rev. 2007; 218:126-34. DOI: 10.1111/j.1600-065X.2007.00536.x. View

5.
Goldfinger L, Han J, Kiosses W, Howe A, Ginsberg M . Spatial restriction of alpha4 integrin phosphorylation regulates lamellipodial stability and alpha4beta1-dependent cell migration. J Cell Biol. 2003; 162(4):731-41. PMC: 2173787. DOI: 10.1083/jcb.200304031. View